Nederland
Interactieve versie
U vindt veel meer informatie per bedrijf en veel meer bedrijven. Ook kunt u filters toepassen en exporteren naar Excel.
Bekijken
Byondis B.V.
Nijmegen - Gelderland
www.byondis.com
Naam
Byondis B.V.
Website
www.byondis.com
Sector
Natuurwetenschappelijk onderzoek en experimentele ontwikkeling
Werkenden
100-499 wn.
Adres
Microweg 22
Postcode
6545CM
Plaatsnaam
Nijmegen
1 16 2 2025 24 3 6 7 a ability about accelerat acros adc addres advanc advanced advances affected against aim all allow alon an and announced announces antibodies/adcs antibody antibody-based antibody-drug appointment are art as asset at axis based berg best best-in-clas bind block breaking breakthrough bring broad busines by byon4228 byon4228.002 byon4413 byondis cancer candidates capabilities carer cd123 cd47 cd47-sirpα cell checkpoint chief christoph clas clinical clos combination commercial condition conjugates contact control cookie cytotoxic d data dedicated deliver den destruction develop development directed director discovery diversity dos dosed drug efficacy efficiency efficiently effort enabl enhanced escalation escap eu evaluat exist expansion experienced exploit expressed facilities fda featured finding first follow for found from full fully fully-integrated function general generation get gmp hem highly hom hous how if immun immune-stimulat immuno immuno-oncology immunology important in-hous includ includes index indication inhibitor innovativ inspected/approved integrated interview intrigu investor it its know korpus larg large-scal lead learn leverag limitation linkedin linker lives mab macrophages malignancies management manufactur masked mba meaningful media messag metastatic moa moas modalities monoclonal mor multi multi-specific myeloid ned new novel officer on oncology one optimiz optimized or our owned patient payload pembrolizumab pharmacodynamic pharmacokinetic phas phd pioner pipelin pivotal platform play policies potentially pre pre-clinical preclinical pres privacy production program promis proprietary protein purchas quality question r raised rang read receptor recognition releas research responsibl revealed robust rol safety scal scienc seamles selectivity sending senior sirpα sirpα-directed solid solution specific sped stag stat state-of-the-art statement stimulat stories supply system target team technologies term that the therapeutic
Vind meer informatie over Byondis B.V. in de interactieve versie